Ketamine Therapy for Mental Health: Evidence and Clinical Use

Ketamine moved from surgical suites to psychiatric clinics faster than almost any treatment in modern mental health history — and the clinical data driving that shift is genuinely striking. This page covers what ketamine therapy is, how it works at the neurological level, the conditions it is used to treat, and the clinical boundaries that distinguish appropriate candidates from those for whom other approaches make more sense. The stakes are real: for patients who have failed two or more antidepressant trials, the question of what comes next is not academic.

Definition and scope

Ketamine is a dissociative anesthetic that has been on the FDA-approved drug list since 1970 — originally for surgical anesthesia. Its psychiatric application arrived decades later, when researchers noticed that sub-anesthetic doses produced rapid reductions in depressive symptoms, sometimes within hours rather than the weeks that conventional medication for mental health typically requires.

Two distinct forms are used clinically. The first is racemic ketamine — the original formulation, administered intravenously (IV) — which remains an off-label treatment. The second is esketamine (brand name Spravato), an intranasal formulation and the S-enantiomer of racemic ketamine, which received FDA approval in 2019 specifically for treatment-resistant depression and, in a separate indication, for major depressive disorder with acute suicidal ideation or behavior (FDA Drug Approval Package, Spravato, NDA 211243). That regulatory distinction matters practically: IV ketamine infusions are administered entirely off-label, meaning insurance coverage is inconsistent and clinical protocols vary by provider.

How it works

The mechanism separates ketamine from every other antidepressant on the market. Standard antidepressants — SSRIs, SNRIs, tricyclics — work primarily on monoamine neurotransmitters: serotonin, norepinephrine, dopamine. Ketamine works primarily on the glutamate system, specifically as an NMDA (N-methyl-D-aspartate) receptor antagonist.

When NMDA receptors are blocked, a downstream cascade activates AMPA receptors and triggers the release of brain-derived neurotrophic factor (BDNF). BDNF promotes synaptogenesis — the growth of new synaptic connections — in the prefrontal cortex and hippocampus, areas consistently shown to atrophy in depression and mood disorders. Research published in Science (Bhagya & Bhagya, 2000; Duman et al., 2012) has described this as a rapid "synaptogenic" effect, which corresponds to the speed of clinical response that distinguishes ketamine from all other available treatments.

The dissociative effects during infusion — a sense of detachment, altered perception, occasionally vivid imagery — are generally temporary and resolve within an hour of administration. They are considered a side effect, not the mechanism of benefit, though some researchers continue to study whether the psychedelic-adjacent experience contributes to outcomes.

Common scenarios

Ketamine therapy is most frequently encountered in four clinical situations:

1. Treatment-resistant depression (TRD): Defined by the National Institute of Mental Health (NIMH) as inadequate response to at least 2 adequate antidepressant trials. This is the primary evidence base for ketamine. Studies published in JAMA Psychiatry have reported response rates of 50–70% in TRD populations after a standard 6-infusion course.
2. Acute suicidal ideation: The speed of action makes ketamine uniquely relevant in crisis intervention contexts. Esketamine's 2019 FDA approval for MDD with acute suicidal ideation acknowledged this property directly.
3. PTSD and trauma-related conditions: Evidence is emerging — not yet at the level of a primary indication — that ketamine reduces hyperarousal and intrusive symptoms in PTSD and trauma-related disorders, likely through the same synaptic remodeling that benefits depression.
4. Bipolar depression: A more cautious use case. Ketamine has demonstrated antidepressant effects in bipolar disorder, but risk of triggering hypomanic or mixed episodes requires careful monitoring and is not yet standard practice.

Decision boundaries

Ketamine therapy is not appropriate for every patient with a difficult-to-treat condition, and the clinical community has developed reasonably clear contraindication profiles.

Contraindications and cautions include:
- Active or history of psychosis, including schizophrenia and psychotic disorders — ketamine's dissociative properties can exacerbate psychotic symptoms
- Uncontrolled hypertension — IV ketamine raises blood pressure acutely
- Active substance use disorder, particularly stimulant or dissociative drug misuse, given ketamine's own abuse potential (DEA Schedule III classification)
- Pregnancy — safety data are insufficient
- History of mania without adequate mood stabilization

The comparison between IV ketamine and intranasal esketamine is also a practical decision boundary. IV ketamine delivers higher bioavailability and allows dose titration in real time; it is the format used in most research trials. Esketamine is self-administered (under clinical observation) and is FDA-approved, which means it is more likely to be covered under structured insurance arrangements consistent with mental health parity laws. The trade-off is that esketamine's evidence base, while strong, is narrower than the broader IV literature.

Duration of benefit is a legitimate open question. A standard IV course — typically 6 infusions over 2–3 weeks — produces remission in a meaningful subset of patients, but effects can fade within weeks to months for others. Maintenance infusions, spaced monthly or as needed, are used in practice, though long-term protocols are still being standardized through mental health research and clinical trials.

Patients considering ketamine therapy are best served by a comprehensive psychiatric evaluation that accounts for full diagnostic history, concurrent medications (particularly MAOIs and benzodiazepines, which interact with ketamine pharmacology), and realistic expectations about what rapid response does — and does not — guarantee about sustained recovery. The treatment fits within a broader framework that may include psychotherapy, ongoing medication management, and social support — not as a standalone resolution to complex psychiatric illness.